What’s Next in Biotech — Regulatory Pathways: Where We Are and Where We're Heading with Elizabeth Jungman, Partner at Hogan Lovells

Join Tim Ehrlich, Chair of Gunderson Dettmer’s Life Sciences practice and host of the “What’s Next in Biotech” series, as he sits down with Hogan Lovells Partner and former senior FDA official Elizabeth Jungman for a candid conversation about where biotech regulatory pathways stand today and where they are headed next.

Drawing on Tim’s deep experience advising life sciences companies and investors and Elizabeth’s unique perspective from her time at the FDA and in private practice, this episode explores how fast-moving science, policy, and AI are reshaping the rules of the game for biotech innovators.

In this episode, Tim and Elizabeth will explore:

• • The FDA’s current role in overseeing biotech innovation and how that role is likely to evolve in the coming years.
  • Recent FDA changes and what companies can practically do now to stay ahead of those shifts.
  • How AI is showing up in the regulatory process and what that means for development timelines, risk, and strategy.

What’s Next in Biotech, hosted by Gunderson Dettmer Partner Tim Ehrlich, features conversations with established leaders in the life sciences industry, offering insights into current market conditions and the key drivers shaping the next generation of successful biotech companies.